AFB MDR SCREEN BY LINE PROBE ASSAY- SPUTUM, BAL, OTHER RESPIRATORY SAMPLES

AFB MDR Screen by Line Probe Assay (LPA) is an advanced molecular diagnostic test used for the rapid detection of multidrug-resistant tuberculosis (MDR-TB). The test identifies genetic mutations associated with resistance to key anti-tuberculosis drugs such as Rifampicin and Isoniazid directly from sputum, bronchoalveolar lavage (BAL), and other respiratory specimens.

This highly sensitive molecular technique enables early identification of drug-resistant tuberculosis, allowing healthcare providers to initiate appropriate treatment strategies without waiting for conventional culture-based drug susceptibility testing. The test plays a critical role in tuberculosis control programs and improves patient outcomes through timely diagnosis.

Benefits of the Test

• Rapid detection of multidrug-resistant tuberculosis.
• Identifies Rifampicin and Isoniazid resistance.
• Provides faster results than conventional culture methods.
• Supports early treatment decisions.
• Helps prevent transmission of drug-resistant TB.
• Highly sensitive molecular diagnostic technique.
• Useful for confirmed or suspected tuberculosis cases.
• Improves clinical management and patient outcomes.

Why Doctors Recommend This Test

Doctors recommend AFB MDR Screen by Line Probe Assay when tuberculosis is suspected or confirmed and there is a need to identify drug resistance rapidly. The test is especially useful in patients with treatment failure, recurrent tuberculosis, contact with MDR-TB cases, or those at high risk for drug-resistant infection.

Early detection of resistance patterns helps clinicians select effective medications and avoid inappropriate treatment regimens.

Preparation Before Test

• No fasting is required.
• Provide a good-quality sputum sample as instructed.
• Early morning sputum samples may be preferred.
• Inform the doctor about ongoing tuberculosis treatment.
• Follow proper sample collection guidelines.
• BAL and respiratory samples should be collected by qualified healthcare professionals.

Normal Reporting Time

Most AFB MDR Screen by Line Probe Assay reports at Focus Diagnostics are available within 2–3 hours after sample processing, depending on laboratory workflow and sample quality.

Who Should Take This Test?

This test may be recommended for:

• Patients with suspected tuberculosis.
• Individuals with recurrent TB infection.
• Patients not responding to TB treatment.
• People exposed to MDR-TB patients.
• Patients with positive AFB findings.
• Individuals requiring rapid drug resistance screening.
• High-risk tuberculosis patients.
• Patients undergoing TB treatment evaluation.

Detailed Information

AFB MDR Screen by Line Probe Assay is a modern molecular diagnostic test designed to detect tuberculosis bacteria and identify genetic mutations responsible for resistance to first-line anti-tuberculosis drugs. Unlike traditional culture methods that may require several weeks, Line Probe Assay provides rapid and reliable results within a significantly shorter period.

Tuberculosis remains a major global health concern, and multidrug-resistant tuberculosis presents additional treatment challenges. MDR-TB occurs when Mycobacterium tuberculosis becomes resistant to at least Rifampicin and Isoniazid, the two most important first-line anti-TB medications. Early identification of resistance is essential for selecting effective treatment regimens and preventing disease progression.

The Line Probe Assay works by detecting specific genetic mutations associated with drug resistance. Molecular amplification techniques are used to analyze bacterial DNA extracted from respiratory specimens. The test provides valuable information regarding resistance patterns, enabling clinicians to tailor therapy according to the patient's needs.

This test is particularly beneficial for patients with persistent symptoms, previous TB treatment, treatment failure, relapse cases, or close contact with individuals diagnosed with MDR-TB. Rapid diagnosis helps reduce delays in treatment initiation and supports public health efforts to control the spread of resistant tuberculosis strains.

Because drug-resistant TB requires specialized treatment approaches, timely identification is critical. The information obtained from Line Probe Assay assists infectious disease specialists, pulmonologists, and public health professionals in developing effective management plans.

At Focus Diagnostics, AFB MDR Screening by Line Probe Assay is performed using advanced molecular diagnostic technology and strict quality standards to ensure accurate, reliable, and clinically meaningful results for tuberculosis management.